Company: HRTX
Filing Date: 2025-04-30
Form Type: DEF 14A
Source: 0000950170-25-060882
Chunk: 16

Company: HERON THERAPEUTICS, INC. /DE/
Filing Date: 2025-04-30
Form: DEF 14A
Chunk 16
---
os, Inc., a wholly owned subsidiary of Celgene Corporation, most recently serving as Managing Director. Prior to its acquisition by Celgene Corporation in 2015, he served as Senior Vice President and General Counsel of Receptos, Inc. From 2012 through its acquisition by Vista Equity Partners Management, LLC in 2013, Mr. Waage served as Vice President, General Counsel and Corporate Secretary at Websense, Inc. From 2008 through its acquisition by AstraZeneca PLC in 2012, he served as Vice President, General Counsel and Corporate Secretary of Ardea Biosciences, Inc. Prior to 2008, Mr. Waage served as a partner at DLA Piper LLP. He received a J.D. degree from the University of San Diego School of Law and a B.A. degree in economics from the University of California, San Diego. The Board has concluded that Mr. Waage should serve as a director based on his experience in regulatory, legal and finance matters.

11

INFORMATION CONCERNING EXECUTIVE OFFICERS Executive officers are elected by our Board and hold office until the earlier of their death, resignation, removal or the election and qualification of a successor. Our executive officers and their ages and positions are as follows:

| Name           |     | Age |     | Position                                            |     | Officer Since |
| Craig Collard  |     |  59 |     | Chief Executive Officer and Director                |     |          2023 |
| Ira Duarte     |     |  56 |     | Executive Vice President, Chief Financial Officer   |     |          2023 |
| Mark Hensley   |     |  42 |     | Executive Vice President, Chief Operating Officer   |     |          2025 |
| William Forbes |     |  63 |     | Executive Vice President, Chief Development Officer |     |          2023 |

The background of Mr. Collard is described above under “Information Concerning the Board of Directors.” Ira Duarte joined Heron as Executive Vice President, Chief Financial Officer in June 2023. Ms. Duarte brings significant experience and expertise in financial leadership to Heron. Prior to joining Heron, Ms. Duarte served in financial leadership roles from 2016 to 2023, most recently as Chief Financial Officer, at Veloxis, a fully integrated specialty pharmaceutical company. Prior to that, Ms. Duarte served as the Corporate Controller at BioDelivery